Thuja announces changes to its Advisory Board
Dr. Werner Cautreels joins and Prof. Dr. Jan van de Winkel steps down from Thuja's Advisory Board
Utrecht, 5 November 2020 – The team of Thuja is delighted and honored to announce that Dr. Werner Cautreels has agreed to join the Advisory Board of Thuja. The Advisory Board consists of seasoned individuals with a track record in academia, medicine and/or industry of high relevance to Thuja's investment focus. Given Dr. Cautreels impressive background and extensive network, we believe that he will be an excellent addition to the Advisory Board.
Background of Dr. Cautreels
After Dr. Cautreels obtained his PhD in chemistry from the University of Antwerp, Belgium and an Executive MBA from Harvard Business School, Massachusetts, USA, he worked at Sanofi, Sterling Winthrop and Nycomed-Amersham in a variety of R&D management positions in Europe and the United States. Dr Cautreels served as Global CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in 2010. Subsequently he was President and CEO of Selecta Biosciences (Boston and Moscow) from July 2010 until his retirement in December 2018.
Dr. Cautreels is now pursuing a portfolio career. Dr Cautreels was a Director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, MA, USA). Until April 2019, Dr Cautreels was Director and Chair of the Audit Committee of Galapagos NV (Mechelen, Belgium), and the President of the Belgian Chamber of Commerce for Russia. He currently serves as Chairman of Cristal Therapeutics and MRM Health, and is a member of the Board of ATB Therapeutics, Accoy Pharmaceuticals and Thrombolytic Science. Dr. Cautreels lives alternatingly in Boston and Brussels.
Departure of Dr. van de Winkel
After serving for more than 12.5 years in the Advisory Board, Prof. Dr. Jan van de Winkel has decided to step down. Prof. Dr. Van de Winkel is CEO of Genmab and the enduring success of Genmab requires his full dedication and focus. We are very grateful to the great contribution that Jan has made. His critical yet supportive attitude has helped us in selecting and building our portfolio, to the benefit of our investors as well as the patients and doctors.